2023-505992-54-00招募中1 期
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Immunotherapy with or without Carboplatin in Participants with Advanced or Metastatic Non‑Small Cell Lung Cancer (Tropion-Lung04)
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 75
- 试验地点
- 17
- 主要终点
- Safety and tolerability of combination treatment with Dato-DXd and immunotherapy with or without up to 4 cycles of carboplatin, as measured by DLTs, TEAEs, SAEs, AESIs, ECOG PS, vital sign measurements, standard clinical laboratory parameters (hematology, clinical chemistry, and urinalysis), ECG parameters, ECHO/MUGA scan findings, and ophthalmologic findings
研究概览
简要总结
To assess the safety and tolerability of combination treatment with Dato-DXd and immunotherapy, with or without up to 4 cycles of carboplatin
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Participant ≥18 years old on the day of signing the ICF (local regulatory requirement to consent should be followed)
- •Histologically or cytologically confirmed diagnosis of advanced or metastatic NSCLC, without EGFR or ALK genomic alterations (not required for squamous histology) and no known genomic alterations in other actionable driver kinases with approved therapies (KRAS mutations eligible). Cohort 4a will enroll participants with squamous histology only; cohorts 5 Part 2A and Part 2B as well as Cohorts 12 and 13 will enroll participants with non-squamous histology only
- •For Cohorts 1 to 4, participants must be treatment-naïve or have received and radiologically progressed after only 1 prior line of systemic chemotherapy, without concomitant immune checkpoint inhibitors for advanced or metastatic NSCLC. Cohorts 4a, 5 to 11 and 14 participants must be treatment-naïve for advanced or metastatic NSCLC. For Cohorts 12 & 13, participants must be CPI-acquired resistant after 1 or 2 prior lines of systemic therapy for advanced or metastatic NSCLC, of which at least 1 prior line of therapy should contain an approved anti-PD-1/PD-L1
- •Willing and able to undergo a mandatory tumor biopsy. A tumor biopsy that was recently collected (within 3 months of screening) after completion of the most recent anticancer treatment regimen may be substituted for the biopsy collected during screening. For Cohorts 12 and 13, a tumor sample taken ≤24 months prior to screening is acceptable.
- •Has measurable disease per RECIST1.1 within 28 days prior to Cycle 1 Day 1
- •Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1 at screening
- •Has adequate bone marrow reserve and organ function at baseline within 7 days prior to Cycle 1 day 1
- •For Cohorts 5 to 14 only: Documented IHC PD-L1 expression per analytically validated Ventana PD-L1 (SP263) IHC assay, 22C3 PharmDx assay, or 28-8 PharmDx assay
排除标准
- •Active or prior documented autoimmune or inflammatory disorders
- •Uncontrolled or significant cardiac disease
- •History of another primary malignancy with exceptions
- •active or uncontrolled hepatitis B or C virus or uncontrolled HIV infection
- •spinal cord compression or clinically active CNS metastases
- •History of (non-infectious) ILD/pneumonitis, including radiation pneumonitis, that required steroids
- •Clinically severe pulmonary compromise resulting from intercurrent pulmonary illness
- •Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
- •Clinically significant corneal disease
研究组 & 干预措施
AZD7789
Test
干预措施: AZD7789 (Drug)
Rilvegostomig, Rilvegostomig
Test
干预措施: Rilvegostomig (Drug)
INFLIXIMAB
Auxiliary
干预措施: INFLIXIMAB (Drug)
CARBOPLATIN
Comparator
干预措施: CARBOPLATIN (Drug)
IMFINZI 50 mg/mL concentrate for solution for infusion.
Test
干预措施: IMFINZI 50 mg/mL concentrate for solution for infusion. (Drug)
Datopotamab deruxtecan
Test
干预措施: Datopotamab deruxtecan (Drug)
volrustomig
Test
干预措施: volrustomig (Drug)
MYCOPHENOLATE MOFETIL
Auxiliary
干预措施: MYCOPHENOLATE MOFETIL (Drug)
结局指标
主要结局
Safety and tolerability of combination treatment with Dato-DXd and immunotherapy with or without up to 4 cycles of carboplatin, as measured by DLTs, TEAEs, SAEs, AESIs, ECOG PS, vital sign measurements, standard clinical laboratory parameters (hematology, clinical chemistry, and urinalysis), ECG parameters, ECHO/MUGA scan findings, and ophthalmologic findings
Safety and tolerability of combination treatment with Dato-DXd and immunotherapy with or without up to 4 cycles of carboplatin, as measured by DLTs, TEAEs, SAEs, AESIs, ECOG PS, vital sign measurements, standard clinical laboratory parameters (hematology, clinical chemistry, and urinalysis), ECG parameters, ECHO/MUGA scan findings, and ophthalmologic findings
次要结局
- Efficacy of combination treatment with Dato-DXd and immunotherapy, with or without up to 4 cycles of carboplatin as measured by ORR, DoR, DCR, PFS, TTR, Best percentage change in the SoD of measurable tumors and OS
- PK of Dato-DXd, durvalumab, AZD2936, MEDI5752 and AZD7789, with or without up to 4 cycles of carboplatin as assessed by plasma concentrations and PK parameters of Dato-Dxd, total anti-TROP2 antibody and DXd (MAAA-1181a). Serum concentrations and PK parameters of durvalumab, AZD2936, MEDI5752 and AZD7789
- Immunogenicity of Dato-DXd, durvalumab, AZD2936, MEDI5752 and AZD7789 with or without 4 cycles of carboplatin as assessed by the prevalence and incidence of Dato-DXd, durvalumab, AZD2936, MEDI5752 and AZD7789 ADA.
研究者
Clinical Study Information Center
Scientific
Astrazeneca AB
研究点 (17)
Loading locations...
相似试验
招募中
3 期
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations2023-507933-12-00Daiichi Sankyo Inc.224
招募中
2 期
A Phase 1b/2, Study of I-DXd in Combination with Atezolizumab with or without Carboplatin in First-line ES‑SCLC2023-509629-36-00Daiichi Sankyo Inc.23
招募中
3 期
A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell lung cancer (NSCLC) after complete removal through surgery2024-512195-35-00AstraZeneca AB119
尚未招募
3 期
A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults with advanced or metastatic TROP2-positive, non-squamous non-small cell lung cancer (NS-NSCLC).2024-520101-39-00AstraZeneca AB13
尚未招募
3 期
Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DO-01)Ovarian Cancer2024-516982-35-00Daiichi Sankyo Inc.182